133 related articles for article (PubMed ID: 25315303)
1. Application of neurophysiological biomarkers for Huntington's disease: evaluating a phosphodiesterase 9A inhibitor.
Nagy D; Tingley FD; Stoiljkovic M; Hajós M
Exp Neurol; 2015 Jan; 263():122-31. PubMed ID: 25315303
[TBL] [Abstract][Full Text] [Related]
2. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Kleiman RJ; Chapin DS; Christoffersen C; Freeman J; Fonseca KR; Geoghegan KF; Grimwood S; Guanowsky V; Hajós M; Harms JF; Helal CJ; Hoffmann WE; Kocan GP; Majchrzak MJ; McGinnis D; McLean S; Menniti FS; Nelson F; Roof R; Schmidt AW; Seymour PA; Stephenson DT; Tingley FD; Vanase-Frawley M; Verhoest PR; Schmidt CJ
J Pharmacol Exp Ther; 2012 May; 341(2):396-409. PubMed ID: 22328573
[TBL] [Abstract][Full Text] [Related]
4. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia.
Hajós M; Hoffmann WE; Kocsis B
Biol Psychiatry; 2008 Jun; 63(11):1075-83. PubMed ID: 18261715
[TBL] [Abstract][Full Text] [Related]
5. Brown Norway rats, a putative schizophrenia model, show increased electroencephalographic activity at rest and decreased event-related potential amplitude, power, and coherence in the auditory sensory gating paradigm.
Tomimatsu Y; Hibino R; Ohta H
Schizophr Res; 2015 Aug; 166(1-3):171-7. PubMed ID: 26004687
[TBL] [Abstract][Full Text] [Related]
6. Lack of mutant huntingtin in cortical efferents improves behavioral inflexibility and corticostriatal dynamics in Huntington's disease mice.
Estrada-Sánchez AM; Blake CL; Barton SJ; Howe AG; Rebec GV
J Neurophysiol; 2019 Dec; 122(6):2621-2629. PubMed ID: 31693428
[TBL] [Abstract][Full Text] [Related]
7. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.
Verhoest PR; Fonseca KR; Hou X; Proulx-Lafrance C; Corman M; Helal CJ; Claffey MM; Tuttle JB; Coffman KJ; Liu S; Nelson F; Kleiman RJ; Menniti FS; Schmidt CJ; Vanase-Frawley M; Liras S
J Med Chem; 2012 Nov; 55(21):9045-54. PubMed ID: 22780914
[TBL] [Abstract][Full Text] [Related]
8. Assessment of motor function, sensory motor gating and recognition memory in a novel BACHD transgenic rat model for huntington disease.
Abada YS; Nguyen HP; Schreiber R; Ellenbroek B
PLoS One; 2013; 8(7):e68584. PubMed ID: 23874679
[TBL] [Abstract][Full Text] [Related]
9. Cholinergic gating of hippocampal auditory evoked potentials in freely moving rats.
Klinkenberg I; Sambeth A; Blokland A
Eur Neuropsychopharmacol; 2013 Aug; 23(8):988-97. PubMed ID: 22974558
[TBL] [Abstract][Full Text] [Related]
10. Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice.
Mantovani S; Gordon R; Li R; Christie DC; Kumar V; Woodruff TM
Hum Mol Genet; 2016 May; 25(9):1780-91. PubMed ID: 26908618
[TBL] [Abstract][Full Text] [Related]
11. Long-lasting auditory gating deficit accompanied by GABA(B) receptor dysfunction in the hippocampus after early-life limbic seizures in rats.
Tsai ML; Crutchley M; Boyce R; Ma J; Boon F; Cain DP; Leung LS
Physiol Behav; 2012 Jun; 106(4):534-41. PubMed ID: 22504497
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 9A Inhibition Facilitates Corticostriatal Transmission in Wild-Type and Transgenic Rats That Model Huntington's Disease.
Chakroborty S; Manfredsson FP; Dec AM; Campbell PW; Stutzmann GE; Beaumont V; West AR
Front Neurosci; 2020; 14():466. PubMed ID: 32581668
[TBL] [Abstract][Full Text] [Related]
13. Auditory sensory processing deficits in sensory gating and mismatch negativity-like responses in the social isolation rat model of schizophrenia.
Witten L; Oranje B; Mørk A; Steiniger-Brach B; Glenthøj BY; Bastlund JF
Behav Brain Res; 2014 Jun; 266():85-93. PubMed ID: 24613239
[TBL] [Abstract][Full Text] [Related]
14. Assessment of auditory sensory processing in a neurodevelopmental animal model of schizophrenia--gating of auditory-evoked potentials and prepulse inhibition.
Broberg BV; Oranje B; Glenthøj BY; Fejgin K; Plath N; Bastlund JF
Behav Brain Res; 2010 Dec; 213(2):142-7. PubMed ID: 20417666
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
[TBL] [Abstract][Full Text] [Related]
16. Auditory sensory gating in hippocampus and reticular thalamic neurons in anesthetized rats.
Krause M; Hoffmann WE; Hajós M
Biol Psychiatry; 2003 Feb; 53(3):244-53. PubMed ID: 12559658
[TBL] [Abstract][Full Text] [Related]
17. Effects of phencyclidine on auditory gating in the rat hippocampus and the medial prefrontal cortex.
Dissanayake DW; Zachariou M; Marsden CA; Mason R
Brain Res; 2009 Nov; 1298():153-60. PubMed ID: 19699183
[TBL] [Abstract][Full Text] [Related]
18. Translational utility of rodent hippocampal auditory gating in schizophrenia research: a review and evaluation.
Smucny J; Stevens KE; Olincy A; Tregellas JR
Transl Psychiatry; 2015 Jun; 5(6):e587. PubMed ID: 26101850
[TBL] [Abstract][Full Text] [Related]
19. PDE2 and PDE10, but not PDE5, inhibition affect basic auditory information processing in rats.
Reneerkens OA; Sambeth A; Blokland A; Prickaerts J
Behav Brain Res; 2013 Aug; 250():251-6. PubMed ID: 23688598
[TBL] [Abstract][Full Text] [Related]
20. C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.
Wang PX; Li ZM; Cai SD; Li JY; He P; Huang Y; Feng GS; Luo HB; Chen SR; Liu PQ
Acta Pharmacol Sin; 2017 Sep; 38(9):1257-1268. PubMed ID: 28649129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
